Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 2657 of 3330
Next
>>
>
66401 to 66425 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
BT-20	TNBC	Basal A	Sirolimus	MTOR	MTOR	6.67	uM	5902.069	0.6881	0.4324	1.1199
BT-20	TNBC	Basal A	Sirolimus	MTOR	MTOR	33.3	uM	5902.069	0.6628	0.3853	1.1199
BT-20	TNBC	Basal A	Sirolimus	MTOR	MTOR	0.000427	uM	5903.068	0.9164	0.8454	1.0852
BT-20	TNBC	Basal A	Sirolimus	MTOR	MTOR	0.00213	uM	5903.068	0.7819	0.5943	1.0852
BT-20	TNBC	Basal A	Sirolimus	MTOR	MTOR	0.0107	uM	5903.068	0.7849	0.5999	1.0852
BT-20	TNBC	Basal A	Sirolimus	MTOR	MTOR	0.0533	uM	5903.068	0.8601	0.7406	1.0852
BT-20	TNBC	Basal A	Sirolimus	MTOR	MTOR	0.267	uM	5903.068	0.7750	0.5813	1.0852
BT-20	TNBC	Basal A	Sirolimus	MTOR	MTOR	1.33	uM	5903.068	0.6720	0.3866	1.0852
BT-20	TNBC	Basal A	Sirolimus	MTOR	MTOR	6.67	uM	5903.068	0.6894	0.4197	1.0852
BT-20	TNBC	Basal A	Sirolimus	MTOR	MTOR	33.3	uM	5903.068	0.5583	0.1688	1.0852
BT-20	TNBC	Basal A	Sirolimus	MTOR	MTOR	167	uM	5903.068	0.6183	0.2842	1.0852
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	0.0000853	uM	5906.069	0.9978	0.9942	0.7682
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	0.000427	uM	5906.069	1.0214	1.0560	0.7682
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	0.00213	uM	5906.069	0.9079	0.7635	0.7682
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	0.0107	uM	5906.069	0.7222	0.3093	0.7682
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	0.0533	uM	5906.069	0.6155	0.0633	0.7682
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	0.267	uM	5906.069	0.6371	0.1120	0.7682
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	1.33	uM	5906.069	0.6851	0.2223	0.7682
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	6.67	uM	5906.069	0.6497	0.1408	0.7682
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	33.3	uM	5906.069	0.5732	-0.0307	0.7682
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	0.000427	uM	7797.068	1.0124	1.0683	0.3664
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	0.00213	uM	7797.068	0.9126	0.5583	0.3664
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	0.0107	uM	7797.068	0.8143	0.1414	0.3664
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	0.0533	uM	7797.068	0.7101	-0.2143	0.3664
BT-474	HER2amp	Luminal	Sirolimus	MTOR	MTOR	0.267	uM	7797.068	0.7576	-0.0627	0.3664

|<
<<
Previous
Page 2657 of 3330
Next
>>
>
66401 to 66425 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)